Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Portfolio Pulse from Vandana Singh
Apellis Pharmaceuticals and Swedish Orphan Biovitrum released positive Phase 3 study results for pegcetacoplan in treating rare kidney diseases. The study met its primary endpoint, showing a significant reduction in proteinuria. Both companies plan to submit marketing applications in 2025.
August 08, 2024 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apellis Pharmaceuticals' pegcetacoplan met the primary endpoint in a Phase 3 study for rare kidney diseases, showing a significant reduction in proteinuria. The company plans to submit a supplemental new drug application to the FDA in early 2025.
The positive Phase 3 results and plans for FDA submission are likely to boost investor confidence and positively impact Apellis' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Swedish Orphan Biovitrum (Sobi) reported positive Phase 3 results for pegcetacoplan in treating rare kidney diseases. The company plans to submit a marketing application to the European Medicines Agency in 2025.
The positive study results and future EMA submission plans are likely to positively impact Sobi's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 80